NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 410-413

  Ellis, Peter M ^a   Shepherd, Frances A ^b   Laurie, Scott A ^c   Goss, Glenwood D ^c   Olivo, Martin ^d   Powers, Jean ^d   Seymour, Lesley ^d   Bradbury, Penelope A ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Queen's Cancer Research Institute   (Canada)

Author keywords

Chemotherapy; Insulin like growth factor; Monoclonal antibody; Phase I clinical trial; Small cell lung cancer

Indexed keywords

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 84894597736     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000058     Document Type: Article

References (15)

1. American Cancer Society, Cancer Facts and Figures 2012. Atlanta: American Cancer Society. 2012.
2. Shepherd FA, Crowley J, Van Houtte P, et al.; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-1077.
3. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 1999;17:1794-1801.
4. Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987;5:1401-1409.
5. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.
6. Niell HB, Herndon JE II, Miller AA, et al.; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759.
7. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 1987;5:1864-1873.
8. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol 2007;19:103-108.
9. Quinn KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;271:11477-11483.
10. Izycki T, Chyczewska E, Naumnik W, Ossolinska M. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol Res 2006;16:49-54.
11. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010;12:361-371.
12. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2010;28:7500.
13. Arnold AM, Seymour L, Smylie M, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-4284.
14. Lee S-M, Woll PJ, James LE, et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC): PRS-04. J Thor Oncol 2007;2:S306-S7 10.1097/01.JTO.0000283089.56099.79.
15. Langer CJ, Albert I, Kovacs P, et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). ASCO Meeting Abstracts 2011;29:7001.